WT1-126_134
Wilms Tumor 1 (WT1) peptide epitope RMFPNAPYL (aa 126-134)
RMFPNAPYL Amino Acids · MW: 1107.6
Amino Acids
RMFPNAPYL
Molecular Weight
1107.6
Half-life
minutes-hours
Research Score
4.2
Studies
92
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is WT1-126_134?
A canonical HLA-A*0201-restricted WT1 peptide used in leukemia and solid-tumor vaccine studies. It is designed to elicit WT1-specific cytotoxic T cells against overexpressing tumor cells.
Key Benefits & Mechanisms
WT1-specific CD8+ T-cell priming
tumor-selective antigen targeting
useful for immune monitoring
Research Summary
Multiple human studies have shown the WT1 epitope can expand WT1-reactive T cells, especially when combined with adjuvants. Clinical responses are variable, but immunogenicity is well documented.
Related Peptides
PADRE
Pan HLA-DR-binding helper T-cell epitope
PADRE is a synthetic promiscuous CD4+ helper T-cell epitope designed to bind many HLA-DR alleles. It is widely used in peptide vaccine research to improve helper T-cell priming and strengthen responses to linked antigens.
Vaccine PeptidesSIINFEKL
Ovalbumin 257-264 epitope (SIINFEKL)
SIINFEKL is a classic MHC class I epitope derived from chicken ovalbumin. It is one of the most widely used model peptides for studying antigen presentation, cytotoxic T-cell priming, and peptide vaccine platforms.
Vaccine PeptidesAAGIGILTV
MART-1/Melan-A 26-35 epitope
AAGIGILTV is a well-known HLA-A2-restricted epitope from the melanocyte differentiation antigen MART-1/Melan-A. It has been studied in melanoma vaccine research to generate antigen-specific T-cell responses against tumor cells.
Vaccine PeptidesHPV16 E7(11-20)
Human papillomavirus type 16 E7 11-20 epitope
HPV16 E7(11-20) is a documented cytotoxic T-cell epitope derived from the HPV16 E7 oncoprotein. It has been used in therapeutic HPV vaccine research to stimulate epitope-specific cellular immunity.
Vaccine Peptides